Goldman Sachs’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Goldman Sachs’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,800	Closed	-$309K	–	6612
2021 Q2	$309K	Hold	18,800	–	–	﹤0.01%	5504
2021 Q1	$415K	Buy	+18,800	New	+$513K	﹤0.01%	5249

Goldman Sachs's TCRR Position: Q2 2023 in Review

Goldman Sachs sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 10,765 shares — an estimated $16.1K sold.

Goldman Sachs first reported a position in TCRR in Q1 2019 and held it in 13 quarters. The position peaked at $8.41M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Goldman Sachs reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 10,765 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $16.1K.
Goldman Sachs first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 13 quarters.
Goldman Sachs's TCR2 Therapeutics Inc. Common Stock position peaked at $8.41M in Q1 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.